Literature DB >> 11555026

Development of low-turnover bone diseases after parathyroidectomy and autotransplantation.

A Yajima1, Y Ogawa, A Ikehara, T Tominaga, T Inou, O Otsubo.   

Abstract

Parathyroidectomy and immediate autotransplantation (PTX-AT) has been shown to decrease bone pain and increase bone mineral density. However, adynamic bone disease (ABD) has been predicted to develop if the serum intact parathyroid hormone (i-PTH) level remains lower than normal for a long period of time. Therefore, we investigated the bone histology of patients whose serum i-PTH levels did not increase over 70 pg/mL for 1 year after PTX-AT. Four chronic hemodialysis patients were investigated. The serum intact osteocalcin (i-OC) level was measured and histomorphometry for cancellous bone was performed 1 year after the operation. Tetracycline hydrochloride was administered in the 12 weeks after PTX-AT. The serum i-PTH levels were 20.5 +/- 15.0 pg/mL and i-OC levels were 19.5 +/- 0.9 ng/mL. Histomorphometric analyses showed the osteoclast surface to be 0.1% in two cases and 0% in the other two cases, the eroded surface was 7.7 +/- 6.1%, and the fibrosis volume and osteoblast surface were 0% in all four cases. Osteoid volume, osteoid surface and osteoid thickness were lower in cases 1-3, but higher in case 4. All tetracycline labelings were in contact with the mineralization front in cases 1 and 3, but some were not in cases 2 and 4. Serum i-PTH and i-OC levels indicated that ABD developed in these four cases. Histomorphometric analyses revealed that ABD developed in case 1, while either ABD or low-turnover osteomalacia developed in cases 2 and 4, and low-turnover osteomalacia was observed in case 3 after PTX-AT. In conclusion, i-PTH should not be maintained at lower levels to avoid low-turnover bone diseases.

Entities:  

Mesh:

Year:  2001        PMID: 11555026     DOI: 10.1046/j.1442-2042.2001.00340.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  6 in total

1.  Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study.

Authors:  K Sumida; Y Ubara; J Hoshino; K Mise; N Hayami; T Suwabe; M Kawada; A Imafuku; R Hiramatsu; E Hasegawa; M Yamanouchi; N Sawa; K Takaichi
Journal:  Osteoporos Int       Date:  2015-11-02       Impact factor: 4.507

2.  Adynamic bone disease-bone and beyond.

Authors:  Vincent M Brandenburg; Jürgen Floege
Journal:  NDT Plus       Date:  2008-06

Review 3.  Secondary and Tertiary Hyperparathyroidism in Chronic Kidney Disease: An Endocrine and Renal Perspective.

Authors:  Manju Chandran; Jiunn Wong
Journal:  Indian J Endocrinol Metab       Date:  2019 Jul-Aug

4.  The Importance of Biologically Active Vitamin D for Mineralization by Osteocytes After Parathyroidectomy for Renal Hyperparathyroidism.

Authors:  Aiji Yajima; Ken Tsuchiya; David B Burr; Joseph M Wallace; John D Damrath; Masaaki Inaba; Yoshihiro Tominaga; Shigeru Satoh; Takashi Nakayama; Tatsuhiko Tanizawa; Hajime Ogawa; Akemi Ito; Kosaku Nitta
Journal:  JBMR Plus       Date:  2019-10-23

5.  Aluminum overload in the reverse osmosis dialysis era: does it exist?

Authors:  Mei-Yin Chen; Shih-Hsiang Ou; Nai-Ching Chen; Chun-Hao Yin; Chien-Liang Chen
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

6.  Serum bone resorption markers after parathyroidectomy for renal hyperparathyroidism: correlation analyses for the cross-linked N-telopeptide of collagen I and tartrate-resistant acid phosphatase.

Authors:  Kuo-Chin Hung; Chung-Yu Huang; Chuan-Chieh Liu; Chih-Jen Wu; Shao-Yuan Chen; Pauling Chu; Chia-Chao Wu; Lan Lo; Liang-Kuang Diang; Kuo-Cheng Lu
Journal:  ScientificWorldJournal       Date:  2012-07-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.